Recently, biological agents targeting type 2 inflammation have been continuously developed for refractory CRSwNP patients with poor effects of conventional anti‐inflammatory and surgical treatment, and anti IgE monoclonal antibodies—Omalizumab and anti IL‐4 receptor α (IL‐4 receptor α), monoclonal antibodies Dupilumab, anti IL‐5 monoclonal antibodies Mepolizumab and anti IL‐5 receptor α (IL‐5 receptor α). This evidence concerns the gene IL5 and chronic rhinosinusitis with nasal polyps.